Combination targeted therapy that simultaneously inhibited more than one signaling pathway overcame intrinsic resistance to trastuzumab, demonstrating that the cancer phenotype in general is sustained by more than a single oncogenic pathway or process.41 Our data show that DOK6 has a key role in supporting cancer development and growth, and suggest that combination therapy from the outset to inhibit intersecting pathways and processes, rather than sequential monotherapy, may improve therapeutic outcomes for gastric cancer patients. Here, DOK6 is linked to cancer.